Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients

Liver International

Volumn 36, Issue 2, 2016, Pages 189-197

  Everson, Gregory T ^a   Sims, Karen D ^b   Thuluvath, Paul J ^c   Lawitz, Eric ^d   Hassanein, Tarek ^e   Rodriguez Torres, Maribel ^f   Desta, Tadesse ^g   Hawkins, Trevor ^h   Levin, James M ⁱ   Hinestrosa, Federico ^j   Rustgi, Vinod ^k   Schwartz, Howard ^l   Younossi, Zobair ^m   Webster, Lynn ⁿ   Gitlin, Norman ^o   Eley, Timothy ^b   Huang, Shu Pang ^b   Mcphee, Fiona ^b   Grasela, Dennis M ^b   Gardiner, David F ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c MERCY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e Southern California Liver Centers   (United States)

^f Fundacion de Investigacion   (United States)

^g Precision Research Institute   (United States)

^h Southwest CARE Center   (United States)

ⁱ Dean Foundation for Health   (United States)

^j ORLANDO IMMUNOLOGY CENTER   (United States)

^k UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^l MIAMI RESEARCH ASSOCIATES   (United States)

^m INOVA FAIRFAX HOSPITAL   (United States)

ⁿ PRA HEALTH SCIENCES   (United States)

^o Atlanta Gastroenterology Associates   (United States)

more..

Author keywords

Direct acting antiviral; Drug combination; Liver disease; Therapy

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BECLABUVIR; BILIRUBIN; DACLATASVIR; GLUCOSE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PHOSPHATE; RIBAVIRIN; VIRUS RNA; 8-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-1,1A,2,12B-TETRAHYDRO-11-METHOXY-1A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-5-CARBOXAMIDE; ANTIVIRUS AGENT; BENZAZEPINE DERIVATIVE; BMS-790052; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS C; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; THROAT TIGHTNESS; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; BENZAZEPINES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INDOLES; ISOQUINOLINES; MALE; MIDDLE AGED; RIBAVIRIN; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84955481913     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12964     Document Type: Article

References (28)

1. World Health Organization. Hepatitis C key facts. WHO factsheet No 164. July 2013. 2013.
2. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55(Suppl. 1): S10-5.
3. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33(Suppl. 1): 56-62.
4. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at http://www.hcvguidelines.org/fullreport/hcv-testing-and-linkage-care. Accessed 27 November 2015.
5. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236.
6. Jacobson IM, McHutchison JG, Dusheiko G, etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
7. Poordad F, McCone J Jr, Bacon BR, etal. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
8. Jacobson IM, Dore GJ, Foster GR, etal. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
9. Lawitz E, Mangia A, Wyles D, etal. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
10. Gao M, Nettles RE, Belema M, etal. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
11. McPhee F, Sheaffer AK, Friborg J, etal. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012; 56: 5387-96.
12. Kadow J, Gentles RG, Ding M, etal. Discovery of BMS-791325, an allosteric NS5B replicase inhibitor for the treatment of hepatitis C virus [abstract]. 243rd ACS National Meeting and Exposition 2012: Abstract MEDI-23.
13. Everson GT, Sims KD, Rodriguez-Torres M, etal. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420-9.
14. Nettles RE, Gao M, Bifano M, etal. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54: 1956-65.
15. McPhee F, Friborg J, Levine S, etal. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 2012; 56: 3670-81.
16. Fridell RA, Wang C, Sun JH, etal. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: invitro and invivo correlations. Hepatology 2011; 54: 1924-35.
17. McPhee F, Falk P, Lemm J, etal. Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-alfa and ribavirin. J Hepatol 2012; 56(Suppl. 2): S473.
18. Lok AS, Gardiner DF, Lawitz E, etal. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
19. Lok AS, Gardiner DF, Hezode C, etal. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60: 490-9.
20. Suzuki Y, Ikeda K, Suzuki F, etal. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-62.
21. Chayama K, Takahashi S, Toyota J, etal. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-8.
22. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, etal. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
23. Guedj J, Rong L, Dahari H, Perelson AS. A perspective on modelling hepatitis C virus infection. J Viral Hepat 2010; 17: 825-33.
24. ™ (Simeprevir) Prescribing Information. 2014.
25. Afdhal N, Zeuzem S, Kwo P, etal. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
26. Ferenci P, Bernstein D, Lalezari J, etal. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. NEngl J Med 2014; 370: 1983-92.
27. Poordad F, Sievert W, Mollison L, etal. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015; 313: 1728-35.
28. Muir A, Poordad F, Lalezari JP, etal. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C genotype 1 infection with compensated cirrhosis. JAMA 2015; 313: 1736-44.